(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) and The University of Texas MD Anderson Cancer Center announced a multi-year strategic development collaboration to expand the evaluation of ...

Bethesda-based Sucampo Pharmaceuticals Inc. agreed to acquire Japan’s R-Tech Ueno Ltd. in a deal valued at about $276 million (33 billion yen), buying a company controlled by Sucampo’s ...

MD, PhD, former Vice President in the Medicines Development Group at Pfizer, has joined the company as Vice President of Medical Affairs. Purdue Pharma, L.P. logo. "Gail brings to Purdue strong ...

Hookipa Pharma, a Phase 2 biotech developing T cell immunotherapies for various cancers, announced terms for its IPO on Monday. The New York, NY-based company plans to raise $100 million by ...

The University of Texas MD Anderson Cancer Center, Artios Pharma Limited and ShangPharma Innovation today announce the in-licensing by Artios of a small-molecule ATR inhibitor program, developed ...

The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical ...

Potomac-based IGC Pharma Inc. Thursday announced enrollment of patients at the Baycrest Academy for Research and Education in Toronto as part of the company’s ongoing Phase 2 trial investigating ...

Press release N 6 / 2019 of 27 March 2018Top Pharma Manager Stefan M. Manth, MD, to become CEO of MOLOGEN AG - To turn therapeutic value created into commercial success - Read-out of pivotal phase ...

Intouch Solutions, a marketing agency servicing the pharmaceutical industry, and MD Mindset, a life sciences and health care marketing intelligence firm, today announced an agreement to deliver ...